New Weapons Against Cardiorenal Syndrome New Weapons Against Cardiorenal Syndrome

Cardiovascular outcomes trials show beneficial effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on both cardiovascular and renal outcomes, sparking renewed interest in cardiorenal syndrome.Medscape Diabetes & Endocrinology
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Diabetes & Endocrinology Commentary Source Type: news